1st Quarter - Termination

ROCK & ASSOCIATES for WELLNESS PHARMACY

Firm
Client
Income
—
Expenses
—
Terminated
Jan 31, 2022

No amount is shown when the filer reports less than $5,000 for the period, which the form does not ask them to state.

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

Appropriations and report language related to the funding of FDA as it affects compounding pharmacies.

LobbyistCovered position, as disclosed
JAMES W ROCK —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

Issues related to the NASEM report to the FDA on compounded bioidentical hormones, and on the implementation of the MOU under section 503A of the FDCA.

LobbyistCovered position, as disclosed
JAMES W ROCK —

Contacted: SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Pharmacy PHA

Issues related to the federal regulation of compounding pharmacy. No specific legislation at this time.

LobbyistCovered position, as disclosed
JAMES W ROCK —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details. Other amounts

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.